Some clinical implications of adrenergic receptors in the urinary tract.
D000322:Adrenergic Agonists / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D001337:Autonomic Agents / Q000627:therapeutic use*; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008297:Male; D008525:Medroxyprogesterone / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D011374:Progesterone / Q000009:adverse effects / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D011467:Prostate / Q000294:innervation; D011472:Prostatitis / Q000188:drug therapy; D011941:Receptors, Adrenergic; D013881:Thioridazine / Q000627:therapeutic use; D014513:Ureter / Q000294:innervation; D014521:Urethra / Q000294:innervation; D001743:Urinary Bladder / Q000294:innervation; D014550:Urinary Incontinence, Stress / Q000188:drug therapy; D014551:Urinary Tract / Q000294:innervation*; D014570:Urologic Diseases / Q000188:drug therapy / Q000503:physiopathology*
D000322:Adrenergic Agonists; D000317:Adrenergic alpha-Antagonists; D001337:Autonomic Agents; D004967:Estrogens; D011941:Receptors, Adrenergic; D010643:Phenoxybenzamine; D011374:Progesterone; D011433:Propranolol; D008525:Medroxyprogesterone; D013881:Thioridazine; D007099:Imipramine; D010646:Phentolamine